Company launches the first-of-its-kind, AI-powered clinical trial feasibility platform to accelerate clinical trial startup – part of its mission to markedly reduce time taken and cost to run trials

Biogenesis today launched from stealth, backed by Jack Altman’s Alt Capital. Biogenesis builds an automated feasibility platform for clinical trials, enabling more efficient and streamlined clinical trial operations. The company’s technology houses a live ecosystem of high-performing clinical research sites and investigators, matching pharmaceutical organizations to the right sites with target patient populations for their studies, in a historically fragmented environment.

Approximately 8 years and $2 billion are required to bring a single drug to market in the US, with the largest costs stemming from operational expenses. Sponsors and Clinical Research Organizations (CROs) find themselves burdened with unnecessary obstacles when navigating site selection and assessing feasibility using inaccurate questionnaires, resulting in unfit sites chosen, trial delays, and exponential cost increases. Emerging biopharma is particularly burdened by the rapid proliferation of Site Management Organizations (SMOs) in recent years. The limited infrastructure for maintaining vendor relationships and identifying the right sites that already engage target patient populations results in fewer patients getting the treatment they need.

“Our objective is to substantively increase the output of the pharmaceutical industry through the application of technology to one of the most costly and inefficient aspects of drug development,” said Dietrich A. Stephan, Ph.D., the Company’s Chairman. “Through our technology, we plan to make a meaningful impact on the lives of people suffering and dying from a variety of diseases across the globe,” continued Stephan.

Biogenesis is building an autonomous platform for faster, more accurate site selection, leveraging an ecosystem of high-performing sites to fast-track clinical trials for Sponsors and CROs. With Biogenesis, Sponsors and CROs gain access to a rapidly expanding, live repository of high-enrolling sites across the US, APAC, UK, and CEE, and get matched directly based on target patient populations for their study, saving months during study startup. Sites unlock the AI-powered feasibility tools they need to make their ops more efficient and win more studies. Patients receive new treatments at the speed of innovation.

Altman’s investment enabled Biogenesis to accelerate its product development towards a suite of site-specific, AI-enabled tooling to streamline clinical operations, and data-driven feasibility assessment for studies. Biogenesis is launching with the largest live database of high-performing sites for pharma, complete with all operational tooling to support accelerated site selection.

The investment signifies growth for the company and a leap forward for clinical research. With Biogenesis' groundbreaking technology, the future of clinical trials is not just easier—it's faster, more efficient, and poised to revolutionize the way we bring life-saving treatments to patients.

About Biogenesis

Biogenesis is an AI health-tech company on a mission to 10X the pharmaceutical industry’s output to bring life-saving treatments to patients faster. The company’s technology, today, accelerates clinical trial startup and enables Sponsors and CROs to discover the right sites with target patient populations for their studies. Biogenesis matches studies to the right sites through access to one of the largest and most comprehensive live site and investigator databases in the world. The company is backed by leading investors including Alt Capital. Biogenesis is based in Palo Alto, California, and can be found online at mybiogenesis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251020367687/en/